Bleeding & Clotting Disorders Institute, Peoria, Illinois, USA.
Astellas Pharma Global Development (APGD), Northbrook, Illinois, USA.
Haemophilia. 2022 Sep;28(5):784-795. doi: 10.1111/hae.14608. Epub 2022 Jun 21.
GOAL-Hēm is a novel, haemophilia-specific, patient-centred outcome measure (PCOM) based on goal attainment scaling, allowing people with haemophilia (PwH) to set and monitor the attainment of individualized goals for treatment.
To provide a thorough overview of the creation, validation, and development of GOAL-Hēm.
Clinician workshops were held to develop a haemophilia-specific goal menu. Qualitative data from semistructured interviews with PwH and their caregivers guided further revisions to the goal menu (i.e., goal domains and descriptors). A feasibility study was performed including a 12-week, prospective, noninterventional evaluation involving clinicians and PwH at four US haemophilia treatment centres. Finally, the Patient Voice Study gathered feedback from PwH and their caregivers via an online survey, interviews, and a focus group.
The feasibility study validated GOAL-Hēm with successful outcomes in construct/content validity and responsiveness, including a large effect in patient- and clinician-rated goal attainments. The Patient Voice Study led to significant refinement of GOAL-Hēm goals and descriptors, resulting in a more straightforward and relatable menu for PwH and their caregivers. Overall, GOAL-Hēm captured qualitative data in areas important to PwH and employed quantitative methods to evaluate meaningful changes in those areas. The individualized tool was well equipped to handle the complex and chronic nature of haemophilia and was endorsed by PwH, their caregivers, and clinicians.
The GOAL-Hēm development journey may serve as a roadmap for other PCOMs in a variety of settings, including clinical studies, haemophilia treatment centres for care planning, and as a tool to gather real-world evidence.
GOAL-Hēm 是一种新颖的、针对血友病的、以患者为中心的结局测量工具(PCOM),基于目标实现评分法,使血友病患者能够设定和监测个体化治疗目标的实现。
全面介绍 GOAL-Hēm 的创建、验证和开发过程。
临床医生研讨会旨在制定血友病特异性目标菜单。对血友病患者及其照顾者进行半结构式访谈的定性数据指导了对目标菜单(即目标领域和描述符)的进一步修订。在四个美国血友病治疗中心进行了一项可行性研究,包括为期 12 周的前瞻性非干预性评估,涉及临床医生和血友病患者。最后,通过在线调查、访谈和焦点小组,患者声音研究收集了血友病患者及其照顾者的反馈。
可行性研究验证了 GOAL-Hēm 的构建/内容有效性和反应性,包括患者和临床医生评定的目标实现方面的显著效果。患者声音研究导致 GOAL-Hēm 目标和描述符的显著改进,为血友病患者及其照顾者提供了一个更直接和相关的菜单。总体而言,GOAL-Hēm 捕捉到了对血友病患者重要的定性数据,并采用定量方法评估这些领域的有意义变化。该个体化工具很好地处理了血友病的复杂性和慢性特征,并得到了血友病患者、他们的照顾者和临床医生的认可。
GOAL-Hēm 的开发历程可以为其他各种环境下的 PCOM 提供参考,包括临床研究、血友病治疗中心的护理计划以及收集真实世界证据的工具。